Rated 4.2/5 based on 1426 reviews
LIPAGLYN - The novel drug for treating Diabetic Dyslipidemia
combines lipid and glucose lowering effects in one single molecule.
Zydus Group is a fully integrated, global healthcare provider, with strengths all along the pharmaceutical value chain. With a core competence in the field of healthcare, Zydus Group provides total healthcare solutions ranging from formulations, active pharmaceutical ingredients and animal healthcare products to wellness products.
The group has a team of around 1200 research professionals spearheading its research and development programme of which nearly 400 scientists alone are involved in the NME research programme at the Zydus Research Centre, the group’s state-of-the-art R&D centre.
Zydus Group is supported by a team of over 19,000 people worldwide, comprising professionals, research scientists, medical advisors and workers.
For more information visit www.zyduscadila.com
Disclaimer : Lipaglyn is a prescription drug authorised for sale in India only and can be taken only under the advice and guidance of a registered medical practitioner.